Elmiron: Uses, Dosage & Side Effects
An oral glycosaminoglycan that forms a protective coating on the bladder wall, used to treat interstitial cystitis (bladder pain syndrome) with moderate to severe pain and urinary frequency
Elmiron (pentosan polysulfate sodium) is the only oral medication specifically approved for the treatment of interstitial cystitis (IC), also known as bladder pain syndrome (BPS). It is a semi-synthetic glycosaminoglycan that works by forming a protective coating on the inner lining of the bladder wall, helping to restore the damaged mucous barrier. This protective effect reduces the contact between irritating urinary substances and the bladder wall, alleviating the characteristic symptoms of IC including chronic bladder pain, urinary urgency, and increased urinary frequency. Elmiron is approved for use in adults with IC characterized by glomerulations (small hemorrhages) or Hunner lesions in the bladder wall. Treatment requires patience, as clinical improvement typically takes 3 to 6 months of continuous therapy.
Quick Facts: Elmiron
Key Takeaways
- Elmiron (pentosan polysulfate sodium) is the only oral medication specifically approved for interstitial cystitis (bladder pain syndrome), working by forming a protective coating over the damaged bladder lining.
- The standard dose is one 100 mg capsule taken three times daily on an empty stomach (at least 1 hour before or 2 hours after meals), and treatment response should be evaluated after 6 months.
- Long-term use of Elmiron has been associated with a unique pigmentary maculopathy (retinal eye changes) that can affect vision; regular ophthalmologic examinations are strongly recommended during treatment.
- Elmiron has mild anticoagulant properties and should be used with caution in patients with bleeding disorders or those taking blood thinners such as warfarin, heparin, or NSAIDs.
- Clinical improvement typically requires 3 to 6 months of continuous treatment; patients should not discontinue therapy prematurely before adequate time has been given for the medication to work.
What Is Elmiron and What Is It Used For?
Elmiron contains the active substance pentosan polysulfate sodium, a semi-synthetic heparin-like glycosaminoglycan derived from beechwood hemicellulose. After oral administration, a portion of the drug is excreted through the kidneys into the urine, where it adheres to the inner surface of the bladder wall (the urothelium). There, it forms a protective coating that reinforces the glycosaminoglycan (GAG) layer – a natural mucous barrier that normally shields the bladder tissue from the irritating effects of urinary solutes such as potassium, acids, and other substances.
In patients with interstitial cystitis, the GAG layer is thought to be defective or damaged, allowing irritating urinary components to penetrate the bladder wall and trigger inflammation, pain, and nerve hypersensitivity. By replenishing this protective barrier, Elmiron helps to reduce the exposure of underlying bladder tissue to these harmful substances, thereby alleviating the cardinal symptoms of IC: chronic pelvic and bladder pain, a persistent and urgent need to urinate, and increased urinary frequency (including nocturia). The mechanism of action is fundamentally different from that of analgesics or anti-inflammatory drugs, as it addresses the underlying structural deficiency rather than merely masking symptoms.
Interstitial cystitis (IC), also referred to as bladder pain syndrome (BPS) or painful bladder syndrome, is a chronic condition characterized by recurring discomfort or pain in the bladder and surrounding pelvic region. Patients typically experience a persistent sense of pressure or tenderness in the bladder area, accompanied by an urgent and frequent need to urinate – sometimes as often as 40 to 60 times per day in severe cases. The condition is diagnosed primarily based on symptoms and cystoscopic findings, and it affects an estimated 3 to 8 million women and 1 to 4 million men in the United States alone, according to data from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). IC can significantly impair quality of life, affecting sleep, work, social activities, and intimate relationships.
Elmiron is specifically approved for use in adults with interstitial cystitis that is characterized by glomerulations (petechial hemorrhages visible on cystoscopy after hydrodistention) or Hunner lesions (circumscribed, inflammatory lesions on the bladder wall), together with moderate to severe bladder pain and urinary frequency. It was originally approved by the U.S. FDA in 1996 and is the only oral medication specifically indicated for the treatment of IC. It has since been approved in the European Union and numerous other countries worldwide. In clinical trials, approximately 30–40% of patients reported meaningful symptom improvement, with the full therapeutic effect typically emerging between 3 and 6 months of continuous treatment.
It is important to understand that Elmiron is not a pain reliever in the conventional sense and does not provide immediate symptom relief. The protective coating on the bladder wall develops gradually over weeks to months of consistent use. For this reason, clinical guidelines recommend that treatment should be continued for at least 6 months before a decision is made about whether the medication is effective for a given patient. Some patients may begin to notice gradual improvement in pain and urinary symptoms within the first 3 months, but others may require the full 6-month period.
Unlike analgesics (which block pain signals) or anticholinergics (which reduce bladder muscle spasms), Elmiron works by physically coating the bladder wall to restore its natural protective barrier. This unique mechanism targets the presumed underlying cause of IC symptoms rather than providing purely symptomatic relief. As such, it may be used alongside other IC therapies as part of a comprehensive treatment approach.
What Should You Know Before Taking Elmiron?
Contraindications
There are specific situations in which Elmiron must not be used. Understanding these absolute contraindications is essential before starting treatment.
- Hypersensitivity: Do not take Elmiron if you are allergic to pentosan polysulfate sodium or any of the other ingredients in the capsule (microcrystalline cellulose, magnesium stearate, gelatin, or titanium dioxide E171).
- Active bleeding: Do not take Elmiron if you have active bleeding from any source (other than menstruation). Pentosan polysulfate sodium has mild anticoagulant properties that could worsen bleeding.
Warnings and Precautions
Rare cases of pigmentary maculopathy affecting the retina of the eye have been reported with Elmiron use, particularly with long-term treatment. Symptoms may include difficulty reading, visual distortions, changes in color vision, and/or slower adaptation to dim or reduced lighting. Report any vision changes to your doctor immediately. Regular comprehensive eye examinations (including optical coherence tomography, OCT) are recommended for early detection of retinal changes. Your doctor will discuss whether treatment should be continued if retinal changes are identified.
Before and during treatment with Elmiron, talk to your doctor or pharmacist if any of the following apply to you:
- Upcoming surgery: Elmiron has weak anticoagulant properties. Your doctor may advise you to stop taking the medication before any planned surgical procedures to reduce the risk of bleeding complications.
- Bleeding disorders or increased bleeding risk: If you have any condition that affects blood clotting, or if you take medications that inhibit blood coagulation (anticoagulants, antiplatelet agents), use Elmiron with caution. The combination may increase the risk of bleeding.
- History of heparin-induced thrombocytopenia (HIT): If you have ever experienced a decrease in platelet count caused by a medication called heparin, inform your doctor. Pentosan polysulfate sodium is structurally related to heparin, and although HIT has not been specifically reported with Elmiron, caution is warranted.
- Liver impairment: Pentosan polysulfate sodium undergoes partial hepatic metabolism. If you have liver disease or impaired liver function, your doctor should monitor you more closely, as the drug may be processed differently.
- Kidney impairment: A portion of Elmiron is excreted through the kidneys. Patients with reduced kidney function should use the medication with caution and under close medical supervision.
Because of the risk of pigmentary maculopathy, comprehensive baseline eye examinations are recommended before starting Elmiron therapy. Follow-up examinations should be performed at regular intervals (typically every 6 to 12 months) during treatment, and more frequently if any visual symptoms develop. Early detection of retinal changes may allow for timely discontinuation of the drug before significant vision loss occurs.
Pregnancy and Breastfeeding
Elmiron should not be used during pregnancy or while breastfeeding. There are no adequate and well-controlled studies of pentosan polysulfate sodium in pregnant women, and the potential risks to the developing fetus are not fully characterized. In animal reproductive studies, high doses of pentosan polysulfate sodium were associated with adverse developmental effects. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, discuss alternative treatment options with your healthcare provider before starting or continuing Elmiron therapy.
It is not known whether pentosan polysulfate sodium or its metabolites are excreted in human breast milk. Given the potential for adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother. Discuss the risks and benefits with your doctor.
Children and Adolescents
Elmiron is not recommended for use in children and adolescents under 18 years of age, as the safety and efficacy of pentosan polysulfate sodium have not been established in this age group. Interstitial cystitis is predominantly a condition of adults, and pediatric data are insufficient to support a dosing recommendation.
Driving and Operating Machinery
Elmiron has no or negligible effect on the ability to drive or operate machinery. In clinical studies, the medication did not impair psychomotor function or cognitive performance. However, if you experience side effects such as dizziness (which is listed as a common side effect), exercise caution when driving or operating heavy equipment until you know how the medication affects you.
Important Information About Ingredients
Each Elmiron capsule contains less than 1 mmol (23 mg) of sodium, meaning it is essentially sodium-free. This is relevant for patients who are on a sodium-restricted diet. The capsule shell is made of gelatin and contains titanium dioxide (E171) as a whitening agent.
How Does Elmiron Interact with Other Drugs?
Pentosan polysulfate sodium is a heparin-like compound with weak anticoagulant activity. Although it is primarily intended to act locally on the bladder wall, a small amount is absorbed systemically, which means it has the potential to interact with other medications that affect blood coagulation. Formal drug interaction studies with Elmiron are limited, but the following interactions are clinically relevant based on its pharmacological properties and post-marketing experience.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Warfarin and other oral anticoagulants | Additive anticoagulant effect; increased risk of bleeding | Monitor INR closely; dose adjustment may be needed |
| Heparin (unfractionated and LMWH) | Additive anticoagulant effect due to structural similarity | Avoid concurrent use if possible; monitor for bleeding |
| Thrombolytics (e.g., alteplase, streptokinase) | Significantly increased bleeding risk | Avoid combination; discontinue Elmiron before thrombolytic therapy |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Aspirin (acetylsalicylic acid) | Aspirin inhibits platelet function; combined with PPS anticoagulant effect, may increase bleeding risk | Use with caution; monitor for signs of bleeding |
| NSAIDs (e.g., ibuprofen, naproxen) | NSAIDs impair platelet aggregation; additive bleeding risk with Elmiron | Use with caution; consider alternatives for pain management |
| Antiplatelet agents (e.g., clopidogrel) | Additive effect on platelet function; increased bleeding risk | Monitor for bruising and bleeding; inform your doctor |
| Herbal supplements (e.g., ginkgo, garlic, fish oil) | Some supplements have anticoagulant or antiplatelet properties | Disclose all supplements to your doctor; combined use may increase bleeding risk |
It is important to tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, including over-the-counter medications, vitamins, and herbal supplements. While Elmiron does not have significant cytochrome P450 (CYP)-mediated drug interactions, its anticoagulant properties make it essential to consider the cumulative bleeding risk when used alongside other agents that affect hemostasis.
If you require surgery or dental procedures, inform the surgeon or dentist that you are taking Elmiron, as the medication may need to be temporarily discontinued to reduce the risk of excessive bleeding during and after the procedure.
What Is the Correct Dosage of Elmiron?
Always take Elmiron exactly as your doctor has instructed. If you are unsure about any aspect of your treatment, consult your doctor or pharmacist for clarification. The medication should be taken consistently and at regular intervals to maintain effective levels in the urinary system.
Adults
Standard Adult Dosage
Dose: 100 mg (one capsule) taken orally three times daily
Total daily dose: 300 mg per day
Administration: Swallow capsules whole with a full glass of water
Timing: Take at least 1 hour before or 2 hours after a meal (empty stomach)
Duration: Treatment response should be assessed every 6 months. If there is no improvement after 6 months, your doctor may consider discontinuing the medication.
Taking Elmiron on an empty stomach is important because food can reduce the absorption of the medication. Try to space your doses evenly throughout the day – for example, morning, midday, and evening – to maintain consistent drug levels. The capsules should not be opened, crushed, or chewed; they must be swallowed whole.
Elmiron is intended for long-term use. The therapeutic effect develops gradually as the protective coating on the bladder wall accumulates over time. In clinical trials, some patients reported improvement within the first 3 months, but the maximum benefit was typically achieved between 3 and 6 months of continuous treatment. Your doctor will evaluate your response at regular intervals and determine whether to continue, adjust, or discontinue therapy.
Children
Elmiron is not recommended for children and adolescents under 18 years of age. The safety and efficacy of pentosan polysulfate sodium have not been established in the pediatric population, and there are no approved dosing guidelines for this age group.
Elderly
No specific dose adjustment is required for elderly patients. However, older adults may be more susceptible to certain side effects, particularly bleeding complications, due to age-related changes in kidney and liver function and the higher likelihood of concurrent anticoagulant or antiplatelet therapy. Elderly patients should be monitored more closely, and the need for continued treatment should be regularly reassessed.
Missed Dose
If you forget to take a dose of Elmiron, skip the missed dose and take your next dose at the usual time. Do not take a double dose to compensate for the one you missed. If you frequently forget doses, consider setting an alarm or using a pill organizer to help maintain your schedule. Consistent daily dosing is important for optimal therapeutic benefit.
Overdose
If you have taken more Elmiron capsules than prescribed, contact your doctor immediately. In the event of an overdose, the primary concern is an increased risk of bleeding due to the anticoagulant properties of the medication. Stop taking Elmiron if you experience any signs of bleeding (unusual bruising, blood in urine or stool, prolonged bleeding from cuts, or nosebleeds) and seek medical attention. Treatment of overdose is supportive and may include monitoring of coagulation parameters. There is no specific antidote for pentosan polysulfate sodium overdose.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults | 100 mg (1 capsule) | 3 times daily | On empty stomach; evaluate response at 6 months |
| Elderly | 100 mg (1 capsule) | 3 times daily | No dose adjustment; monitor closely for bleeding |
| Children (<18 years) | Not recommended | N/A | Safety and efficacy not established |
| Renal impairment | 100 mg (1 capsule) | 3 times daily | Use with caution; close medical supervision |
| Hepatic impairment | 100 mg (1 capsule) | 3 times daily | Use with caution; monitor liver function |
What Are the Side Effects of Elmiron?
Like all medicines, Elmiron can cause side effects, although not everyone experiences them. The side effects are classified by frequency based on clinical trial data and post-marketing surveillance. Most common side effects are mild to moderate in severity and may improve as your body adjusts to the medication. However, some rare but serious side effects require immediate medical attention.
It is particularly important to be aware of the risk of pigmentary maculopathy (a condition affecting the retina of the eye) associated with long-term Elmiron use. This condition was first identified through post-marketing reports and subsequent epidemiological studies, and it appears to be related to cumulative drug exposure. The risk increases with longer duration of treatment and higher total lifetime doses. Regular ophthalmologic monitoring is therefore essential for all patients receiving Elmiron therapy.
Common
May affect up to 1 in 10 people
- Headache
- Nausea
- Diarrhea
- Abdominal pain and bloating
- Indigestion (dyspepsia)
- Rectal bleeding
- Hair loss (alopecia)
- Dizziness
- Back pain
- Infections and influenza-like illness
- Fluid retention in arms or legs (peripheral edema)
- Weakness (asthenia)
- Pelvic pain
- Increased urinary frequency
- Abnormal liver function tests
Uncommon
May affect up to 1 in 100 people
- Decreased platelet, red blood cell, or white blood cell counts
- Bleeding, including small subcutaneous hemorrhages
- Allergic reactions and increased photosensitivity
- Loss of appetite, weight gain, or weight loss
- Severe mood swings or depression
- Increased sweating, insomnia
- Restlessness
- Abnormal sensations (tingling, burning, numbness)
- Increased tearing, reduced visual acuity (amblyopia)
- Tinnitus (ringing in the ears)
- Difficulty breathing (dyspnea)
- Vomiting, flatulence, constipation
- Mouth ulcers
- Skin rash, enlarged moles
- Joint pain (arthralgia) or muscle pain (myalgia)
Not Known
Frequency cannot be estimated from available data
- Coagulation disorders (disruption of blood clotting)
- Allergic/hypersensitivity reactions
- Abnormal liver function
- Pigmentary maculopathy (retinal changes affecting vision)
Contact your doctor or seek emergency medical care immediately if you experience any of the following: signs of severe allergic reaction (swelling of the face, lips, tongue, or throat; difficulty breathing; severe skin rash with blistering); significant or unexplained bleeding (blood in urine, blood in stool, vomiting blood, heavy nosebleeds, or bruising without injury); sudden changes in vision (blurred vision, difficulty reading, distorted vision, or changes in color perception); or signs of severe liver problems (yellowing of the skin or eyes, dark urine, persistent nausea, or severe abdominal pain).
If you experience any side effects not listed above, or if any of the listed side effects become severe or persistent, contact your doctor or pharmacist. Reporting suspected side effects helps to continuously monitor the benefit-risk balance of the medication and contributes to drug safety.
How Should You Store Elmiron?
Proper storage of Elmiron is essential to ensure the medication retains its potency and safety throughout its shelf life. The following storage guidelines should be followed carefully:
- Temperature: Store at or below 30°C (86°F). Do not freeze the medication.
- Moisture protection: Pentosan polysulfate sodium is sensitive to moisture. Keep the container tightly closed at all times when not removing a capsule.
- Bottle packaging: If your Elmiron comes in a plastic bottle with a child-resistant cap, use the capsules within 45 days of first opening the bottle. Discard any remaining capsules after 45 days, even if they appear unchanged.
- Blister packaging: If your Elmiron comes in blister packs, keep the capsules in their blister strips until you are ready to take them.
- Expiration date: Do not use Elmiron after the expiration date printed on the packaging (Exp.). The expiration date refers to the last day of that month.
- Keep out of reach: Store this medication out of the sight and reach of children.
Do not dispose of medications by flushing them down the toilet or pouring them into drains. Ask your pharmacist about the proper way to dispose of medications you no longer need. These measures help protect the environment. Many pharmacies and local authorities offer medication take-back programs for safe disposal.
What Does Elmiron Contain?
Understanding the full composition of Elmiron is important, particularly for patients with known allergies to specific pharmaceutical excipients. Below is the complete list of ingredients in each capsule:
| Component | Ingredient | Function |
|---|---|---|
| Active substance | Pentosan polysulfate sodium 100 mg | Therapeutic agent; forms protective bladder coating |
| Capsule contents | Microcrystalline cellulose | Filler/binder |
| Capsule contents | Magnesium stearate | Lubricant |
| Capsule shell | Gelatin | Capsule material |
| Capsule shell | Titanium dioxide (E171) | Whitening agent |
Elmiron capsules are white and opaque in appearance. They are available in two packaging formats: plastic bottles with child-resistant closures (containing 90 or 300 capsules) and plastic/aluminum blister packs (containing 90 capsules). Not all pack sizes may be marketed in every country.
The capsules contain less than 1 mmol (23 mg) of sodium per capsule, making them essentially sodium-free. This is important information for patients who need to control their sodium intake due to conditions such as heart failure or hypertension.
Frequently Asked Questions About Elmiron
Elmiron (pentosan polysulfate sodium) is used to treat interstitial cystitis (IC), also known as bladder pain syndrome (BPS). It is specifically approved for adults with IC characterized by glomerulations (small hemorrhages) or Hunner lesions (distinct ulcers) in the bladder wall, along with moderate to severe bladder pain and urinary frequency. It is the only oral medication specifically approved for interstitial cystitis in many countries. Elmiron works by forming a protective coating on the inner lining of the bladder, helping to restore the damaged glycosaminoglycan (GAG) layer.
Elmiron typically requires several months to achieve its full therapeutic effect. Most clinical guidelines recommend evaluating the response after at least 6 months of continuous treatment. Some patients may notice gradual improvement in symptoms such as pain, urgency, and frequency within the first 3 months, but the full benefit is usually seen between 3 and 6 months. Your doctor will assess your response and determine whether to continue therapy. It is important not to discontinue the medication prematurely, as the protective coating on the bladder wall builds up gradually over time.
Yes, Elmiron has been associated with a unique pigmentary maculopathy (retinal changes) that can affect vision, particularly with long-term use. Symptoms may include difficulty reading, distorted vision, changes in color perception, and slower adaptation to dim or reduced lighting. The risk increases with longer duration of use and higher cumulative doses. Research published in peer-reviewed ophthalmology journals has identified this condition as a distinct drug-related toxicity. Regular comprehensive eye examinations including optical coherence tomography (OCT) are strongly recommended for all patients, and you should report any visual changes to your doctor immediately.
Elmiron should be used with caution alongside blood thinners (anticoagulants) such as warfarin or heparin, as it has mild anticoagulant properties itself. The combination may increase the risk of bleeding. If you are taking any anticoagulant medication or drugs that affect blood clotting, including aspirin or NSAIDs, inform your doctor before starting Elmiron. Your doctor may need to monitor your blood clotting parameters (such as INR) more closely and adjust doses of your anticoagulant medication if necessary.
Elmiron should not be used during pregnancy or breastfeeding. There is insufficient data on the safety of pentosan polysulfate sodium in pregnant or breastfeeding women, and the potential risks to the developing fetus or nursing infant are not fully known. Animal studies at high doses have shown adverse effects on fetal development. If you are pregnant, planning to become pregnant, or breastfeeding, discuss alternative treatment options with your doctor before starting or continuing Elmiron.
If you miss a dose of Elmiron, skip the missed dose and take your next dose at the usual scheduled time. Do not take a double dose to make up for the missed one. Consistent dosing is important for optimal results, so try to take your capsules at regular intervals throughout the day. If you frequently forget doses, consider using a pill organizer, setting alarms, or linking your medication schedule to daily activities like meals (remembering to take it at least 1 hour before or 2 hours after eating).
References
- European Medicines Agency (EMA). Elmiron (pentosan polysulfate sodium) – Summary of Product Characteristics. Last updated 2025.
- U.S. Food and Drug Administration (FDA). Elmiron (pentosan polysulfate sodium) Capsules – Prescribing Information. Revised 2024.
- Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome: AUA Guideline Amendment. J Urol. 2022;207(4):806-815.
- Engeler D, Baranowski AP, Borovicka J, et al. EAU Guidelines on Chronic Pelvic Pain. European Association of Urology. 2024.
- Nickel JC, Herschorn S, Whitmore KE, et al. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857-862.
- Pearce WA, Chen R, Jain N. Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium. Ophthalmology. 2018;125(11):1793-1802.
- Hanif AM, Armenti ST, Taylor SC, et al. Phenotypic Spectrum of Pentosan Polysulfate Sodium-Associated Maculopathy: A Multicenter Study. JAMA Ophthalmol. 2019;137(11):1275-1282.
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List, 2023.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Interstitial Cystitis (Painful Bladder Syndrome). 2024.
- Clemens JQ, Erickson DR, Varber MJ, et al. Prevalence and Incidence of Interstitial Cystitis in a Managed Care Population. J Urol. 2013;189(5):1797-1802.
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Urology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent review according to WHO, EMA, and FDA guidelines
Evidence Standard
Level 1A – Based on systematic reviews, randomized controlled trials, and international clinical guidelines (AUA, EAU)
Editorial Independence
No commercial funding or pharmaceutical company sponsorship. All content is independently produced.